

CLINICAL CHARACTERISTICS OF PATIENTS WITH CHRONIC HEPATITIS C INFECTION AT INITIAL PRESENTATION TO TERTIARY CARE IN AN ASIAN MIDDLE-INCOME COUNTRY

Amirah Azzeri¹, Fatiha Hana Shabaruddin², Soek-Siam Tan³, Maznah Dahlui^{4,5}, Scott A McDonald^{6,7}, Adeeba Kamarulzaman⁸ and Rosmawati Mohamed⁹

¹Department of Social and Preventive Medicine, ²Department of Pharmacy, Faculty of Medicine, University of Malaya, Kuala Lumpur; ³Department of Hepatology, Selayang Hospital, Selangor; ⁴Centre of Population Health, Department of Social and Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; ⁵Faculty of Public Health, Universitas Airlangga, Surabaya, Indonesia; ⁶Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands; ⁷School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, Scotland; ⁸Centre of Excellence for Research in AIDS, ⁹Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia

Abstract. Chronic hepatitis C virus (HCV) infection is often asymptomatic until an occurrence of severe liver disease. A descriptive cross-sectional study was conducted of a hospital-based case-series in 2014 on 741 consecutive HCV patients presented at the national referral center in Malaysia, a middle-income Southeast Asian country. Mean age at initial presentation was 48 years (SD =11.5; median = 49) with 541 (73%) males. Prior known exposure to HCV risk factors were intravenous drug use ($n = 271/737$) and blood product transfusion ($n = 237/737$). Genotype distributions were G3 (63.0%), G1 (36.1%), G2 (0.5%), G4 (0.2%) and G6 (0.2%), among the 437 patients tested for HCV genotype. Cirrhosis and non-cirrhotic chronic infection was present in 44% [mean (SD) age = 52 (9) years] and 56% [mean (SD) age = 44 (12) years] patients, respectively. Of the 327 cirrhotic patients, 36% and 14% had de-compensated cirrhosis and hepatocellular carcinoma, respectively. Eighty percent patients were eligible for interferon treatment based on their stage of liver disease, but only 50% of the eligible patients received the treatment. Thus, HCV-infected patients at initial presentation to a tertiary care center in Malaysia reflected delayed presentation with a disproportionately high number of patients with liver cirrhotic. Improving access to clinical care and optimizing treatment with direct acting antiviral drug is essential to reduce the country's burden of hepatitis C.

Keywords: cirrhosis, epidemiology, hepatitis C, middle-income country, Malaysia

Correspondence: Fatiha Hana Shabaruddin, Department of Pharmacy, Faculty of Medicine, University of Malaya, Kuala Lumpur 50603, Malaysia.

Tel: +603 79674700

E-mail: fatiha.shabaruddin@um.edu.my

INTRODUCTION

Globally, 64-103 million people are chronically infected with hepatitis C virus (HCV), while viremia prevalence among adults in Asia Pacific countries is 0.4-1.1% (Gower *et al*, 2014). In Malaysia, 2.5% of the population 15-64 years of age is estimated to be anti-HCV-positive in 2015 and the total adult population with chronic HCV infection estimated at 368,500 (McDonald *et al*, 2014). Worldwide, genotype 1 accounts for 50% of hepatitis C cases followed by genotype 3 (28.6%) (Messina *et al*, 2015). In Malaysia, the predominant HCV genotype is genotype 3 followed by genotype 1 (Mohamed *et al*, 2013; Ho *et al*, 2015).

Generally, 35% of individuals with acute hepatitis C achieve spontaneous viral clearance within two years post-infection, while the remaining progress to chronic HCV infection (Micallef *et al*, 2006). Among the chronically-infected patients, approximately 20% will develop liver cirrhosis within 20-30 years (Westbrook and Dusheiko, 2014), which can lead to hepatic decompensation, hepatocellular carcinoma (HCC) and death, with hepatitis C being the leading cause of HCC and liver transplantations worldwide (Kim and Chang, 2013). Following the onset of cirrhosis, the annual risk of developing decompensated cirrhosis (DC) and HCC is 3-6% and 1-5%, respectively (Maasoumy and Wedemeyer, 2012; Westbrook and Dusheiko, 2014). For patients with DC, the annual mortality risk is 15-20% (Westbrook and Dusheiko, 2014).

Asymptomatic presentation of early hepatitis C infection often leads to many infected individuals being unaware of their infected state (Gupta *et al*, 2015; Zhou *et al*, 2015; Alejandro *et al*, 2016). Patients commonly are admitted into clinical care

after developing clinical sequelae, which are usually irreversible and associated with high morbidity and mortality (Degos *et al*, 2000). The World Health Organization (WHO) recommends direct acting antiviral (DAA) regimen, such as sofosbuvir + velpatasvir, ledipasvir + sofosbuvir and ombitasvir + paritaprevir + ritonavir, as the current drug of choice for treatment of hepatitis C in place of the traditional subcutaneous interferon-based (IFN) therapy (WHO, 2017).

WHO has also established the Global Health Sector Strategy 2016-2021 on viral hepatitis, which recommends all countries to aim for the elimination of viral hepatitis by 2030 (WHO, 2016). In order to develop national policies and strategies to achieve this goal, there is a need to identify the hepatitis C-infected population presenting at a local clinical care center to provide accurate information for the development of national policies for treatment and control of hepatitis C infection.

Hence, this study describes the clinical characteristics and disease stages of chronic HCV-infected patients during initial presentations at the main national tertiary-care referral center in Malaysia.

MATERIALS AND METHODS

Study location and population

A descriptive cross-sectional analysis was conducted of a hospital-based case-series on consecutive HCV patients who presented in 2014 at the national tertiary-care referral center. Selayang Hospital, located in Klang valley, an area with the highest population density in the country (Department of Statistics Malaysia, 2010), is a public healthcare institution and the main tertiary-care referral center for liver diseases in Malaysia. The Hospital has the largest number of hepatologists and gas-

troenterologists among public healthcare institutions and receives referrals for liver cases from all over Malaysia (Hospital Selayang, 2014).

Data on socio-demographic background and clinical characteristics of patients with chronic HCV were collected from Selayang Hospital medical record database from their initial presentation until the end of 2014. Results on HCV viral loads, genotypes and subtypes tests were collected as available in the database.

Chronic HCV patients were classified into cirrhotic and non-cirrhotic types. Cirrhotic patients fulfilled the following criteria: (i) modified histologic activity index score of 6 based on liver biopsy results, and/or (ii) METAVIR score of F4 based on fibroscan result, and/or (iii) aspartate aminotransferase-to-platelet ratio index (APRI) score ≥ 2 (Castéra *et al*, 2005). HCV patients were further classified into compensated and decompensated cirrhosis, with or without HCC. Severity of cirrhosis was graded using the Child-Pugh (CP) classification (Khullar *et al*, 2015). HCC was diagnosed mainly through dynamic imaging studies (multiphasic CT scan or MRI) or liver biopsy, with or without raised alpha-fetoprotein levels (Galle *et al*, 2018).

The study received ethics approval from the National Medical Research Registry and Ethics Committee of Malaysia (NMRR-15-1559-27223).

Laboratory assays

Identification of viral load and genotype (with or without subtype) was conducted using qualitative and quantitative tests for detection of HCV RNA (reverse transcription and PCR-based amplification) and nucleic acid sequencing, respectively (Mohamed *et al*, 2013; Ho *et al*, 2015). The latter results were compared with

sequence information (genotype patterns) deposited at GenBank, and, in some cases, phylogenetic analysis was conducted to specify subtypes of the detected genotype (Mohamed *et al*, 2013; Ho *et al*, 2015).

Data analysis

Data analysis was conducted using SPSS version 22.0 (IBM, Armonk, NY).

RESULTS

There were 741/5,865 (12.6%) patients with active hepatitis C infection treated by the Hepatology Department, Selayang Hospital, Klang valley, Malaysia in 2014. Data were collected for all 741 patients from their first visit to the Hepatology Department until the end of 2014. Of the patients included in this study, 541 (73.0%) were male with mean (SD) age at initial presentation was 48 (11) years (median = 49). The most common age group at initial presentation was 50-59 years ($n = 255$, 34.4%), followed by 40-49 years ($n = 225$, 0.4%). Prior known exposure to HCV risk factors obtained from available data for 737 patients were (in decreasing order of frequency) intravenous drug use (IVDU) ($n = 271$, 36.8%), history of blood or blood products transfusion ($n = 237$, 32.2%), having multiple sexual partners ($n = 123$, 16.7%), tattooing, cupping therapy, acupuncture and/or sharing of personal sharp items with infected individuals ($n = 68$, 9.2%), history of dialysis ($n = 38$, 5.2%), and recipient of organ transplantation ($n = 13$, 1.8%), with some patients having been exposed to multiple HCV risk factors.

Of the 741 patients, 631 and 535 patients were tested for hepatitis B surface antigen (HBsAg) and HIV antibodies, resulting in 34 (5.4%) and 51 (9.5%) patients, respectively being positive. Four (0.5%) patients had triple infections (HCV, hepatitis B and HIV).

Median (range) baseline HCV load was 3.1×10^6 (64 - 861.3×10^6) copies/ml, with high baseline viral load ($>6 \times 10^6$ copies/ml) in 33.3% of chronic HCV patients. Of the 437 patients tested for HCV genotype, genotype 3 was the most common ($n = 275$, 63.0%) followed by genotype 1 ($n = 158$, 36.1%), genotype 2 ($n = 2$, 0.5%), genotype 4 ($n = 1$, 0.2%), and genotype 6 ($n = 1$, 0.2%). Subtypes data were available for 243/275 genotype 3 and 140/158 genotype 1 patients, respectively. Numbers of patients with genotype 3a and 3b were 236 (97%) and 7 (3%), respectively, and with genotype 1a, 1b and 1a/1b were 87 (62%), 49 (35%) and 4 (3%).

At initial presentation, 414 (56%) and 327 (44%) patients were non-cirrhotic [mean (SD) age = 44 (12); median = 45] and cirrhotic [mean (SD) age = 52 (9) years; median = 52 years]. The majority of cirrhotic patients (267, 82%) were <60 years of age and 209 (64%) had compensated cirrhosis [mean (SD) age = 53 (9); years; median = 52 years] while the remaining

(36%) had decompensated cirrhosis [mean (SD) age = 52 (9) years; median = 52 years] (Table 1).

The 118 decompensated cirrhosis patients were further categorized according to CP classification, with 92 (78%) and 26 (22%) patients in CP(B) and CP(C), respectively, while 69 (58%), 62 (45%) and 12 (10%) patients had variceal bleeding, ascites and hepatic encephalopathy, respectively. Of the 327 cirrhotic hepatitis C patients, 45 (14%) had HCC, with 28 (62%), 14 (31%) and 3 (7%) in CP(A), CP(B) and CP(C) category, respectively.

All patients with non-cirrhotic chronic infection and compensated cirrhosis (595/741, 80.3%) were considered clinically eligible for IFN therapy, assuming no other restricting factors for treatment initiation such as comorbidities, refusal and loss to follow-ups. Overall, 123 (20.7%) patients achieved sustained virologic response (SVR) following IFN therapy, among whom 99 (80%) and 24 (20%) were non-cirrhotic and compen-

Table 1
Stages of liver disease at initial presentation of hepatitis C virus -infected patients according to age groups at the national tertiary-care referral center, Malaysia in 2014.

	Stage of liver disease Number of patients		
	Non-cirrhotic	Compensated cirrhosis	Decompensated cirrhosis
Age group (years)			
≤39 ($n = 165$)	140	15	10
40-49 ($n = 225$)	133	55	37
50-59 ($n = 255$)	105	96	54
≥60 ($n = 96$)	36	43	17
Total	414	209	118

sated cirrhotic respectively, with 83, 39 and 1 having HCV genotype 3, 1 and 2 infection, respectively.

There were 262/741 (35%) patients who received treatment for HCV infection, 255 (97%) with IFN-only treatment, 5 (2%) with both IFN and DAA and 2 (1%) with DAA drugs. Among the five patients who received both IFN and DAA, two received IFN, ribavirin and boceprevir for 48-weeks while three patients initially received IFN-based treatment and were subsequently treated with combination regimens of sofosbuvir, daclatasvir and ribavirin for 24 weeks, ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin for 24 weeks and grazoprevir and elbasvir for 12 weeks, respectively. Among the two treatment-naïve patients who received DAA, both were treated with a combination regimen of ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin for 12 weeks. All seven patients who received DAA had HCV genotype 1 infection without cirrhosis.

Among all patients, 479 (64.6%) had viremia but did not receive treatment for HCV infection for the following reasons: (i) ineligible for IFN treatment due to DC and HCC ($n = 146$; 30%), (ii) refused treatment ($n = 89$, 19%), (iii) ineligible for IFN treatment due to such factors as comorbidity, old age or active IVDU ($n = 85$, 18%), and (iv) loss to follow-up ($n = 79$, 16%). The remaining (17%) patients who did not receive treatment because of failure to respond to previous IFN treatment, chose to be treated at other institutions or were awaiting a more affordable DAA.

DISCUSSION

To the best of our knowledge, this is the first and largest study to describe clinical characteristics and disease stages

of chronic HCV-infected patients at initial presentation at tertiary care center in Malaysia. Almost 50% of the hepatitis C patients at the referral center presented with liver cirrhosis, similar to findings from other middle-income countries (de Oliveira *et al*, 2014; Gupta *et al*, 2015).

Based on the European Association for the Study of the Liver (EASL) definition (EASL, 2015), patients who present with significant fibrosis without previous antiviral treatment are considered as delayed presentation of chronic hepatitis C. In this study, 72% of the patients were in this category mainly due to unawareness of their hepatitis C status owing to the subclinical manifestations at early stage of infection; approximately 75-80% of HCV-infected individuals are asymptomatic and only become aware of the infection after serological testing is conducted (Zhou *et al*, 2015). This delayed presentation is particularly of concern among Asian hepatitis C patients, who have no clear risk factors for HCV acquisition compared to other ethnicities, such as Caucasians and Hispanics, but in fact are at risk due to such common practices in Asian countries as acupuncture, sharing shaving kit and use of roadside barber (Nguyen and Nguyen, 2013). These common practices make a risk-based screening strategy challenging as it becomes difficult to identify a high-risk group among the general population, besides the obvious high-risk population of IVDU and those with a history of blood transfusion (Nguyen and Nguyen, 2013; Suthar and Harris, 2015).

The time lag from HCV diagnosis to tertiary care referral is also an important factor in the delayed presentation for clinical management of HCV patients (Yau *et al*, 2015). In Malaysia, there is a paucity of data on referral rate or time between diagnosis of hepatitis C at a primary care

center and presentation at a tertiary care institution, with an estimated referral rate (from primary care to hepatology or gastroenterology specialist care) of 13% in 2016 in 10 of 12 states in Malaysia, the main reason being patient's refusal of IFN therapy, which was previously the main option for HCV treatment before the introduction of DAA drugs within the national public health care system (Ali N, personal communication). Malaysia is an example of a middle-income Asian country that recently (in 2018) has DAA drugs available in the national public healthcare system as the main treatment option for HCV disease, and thus, the treatment rate presented in this study mainly reflected previous use of IFN therapy.

Delayed presentation at advanced stage of liver disease has significant impact on (i) HCV-infected individual in term of lower success rate of treatment (The American Association for the Study of Liver Diseases and Infectious Diseases Society of America, 2017), (ii) healthcare system with regards to higher healthcare utilizations and healthcare costs for disease management (Razavi *et al*, 2013; Myers *et al*, 2014; Azzeri *et al*, 2017), and (iii) society at large due to risk of transmission of an on-going disease in the general population (Hickman *et al*, 2015).

Globally, DAA drugs are now widely used for the treatment of HCV infection. The predominant HCV genotypes in Malaysia are genotype 3 followed by genotype 1, accounting for 99% of all HCV cases (Mohamed *et al*, 2013; Ho *et al*, 2015). This implies that any DAA regimen with proven efficacy for these two genotypes could be adopted within a simple management protocol. Standard use of such DAA regimens for all non-cirrhotic and cirrhotic patients would remove the need for genotyping and thus will further ex-

pedite initiation of treatment for all HCV-infected patients. Hypothetically, if DAA is available as standard HCV treatment for this study population (as compared to the previously use of IFN), the proportion of patients who would be eligible for HCV treatment will rise to 94% compared to 80% due to the wider eligibility for DAA treatment for patients, including those with decompensated cirrhosis, assuming no other restricting factors for treatment initiation, such as comorbidity, refusal and loss of follow-up.

However, HCV-infected patients with advanced liver disease have been known to achieve lower SVR rates with DAA compared to patients without cirrhosis or with compensated cirrhosis (Curry *et al*, 2015; Foster *et al*, 2015). There also is evidence indicating improvements in the symptoms of liver disease after treatment with DAA among patients with decompensated cirrhosis, while CP(C) is not sufficient in preventing the need for liver transplantation or mortality (The American Association for the Study of Liver Diseases and Infectious Diseases Society of America, 2017). This highlights the importance of early presentation for initiation of treatment at the early stages of liver disease among HCV patients.

This study finds, at initial presentation at a tertiary care center, cirrhotic patients were relatively young and the majority of patients with cirrhosis (with or without HCC) were less than 60 years of age. Development of liver cirrhosis among relatively young HCV-infected patients may reflect use of illicit drugs before 20 years of age (Novick *et al*, 1985), which represents the biggest risk factor for HCV transmission in Malaysia (Vicknasingam *et al*, 2009) with liver cirrhosis developing 25 to 30 years following initial exposure to infection (Thein *et al*, 2008).

Several other factors may contribute to the observation of liver cirrhosis at a young age in this study cohort. The majority of the patients were male and infected with HCV genotype 3, factors associated with rapid fibrosis progression in hepatitis C disease (Maasoumy and Wedemeyer, 2012; Toshikuni *et al*, 2014; Lingala and Ghany, 2015). Development of cirrhosis at a relatively young age has also been observed in other studies (Sajja *et al*, 2014; Silva *et al*, 2015; McDonald *et al*, 2017). The development of liver cirrhosis among relatively young patients who are in the working-age group may lead to financial problems to the patients and their families due to loss of income, lower productivity and significant time and costs for treatment (Federico *et al*, 2012; Scalone *et al*, 2015). Patients in this group are potential breadwinners of the family and hepatitis C disease can cause them to be less economically productive owing to reduced ability to work and potential job loss from illness (Scalone *et al*, 2015). Cirrhotic patients spend 7% of their annual income for clinical treatment and have significant time loss from work due hospitalization and visits to clinics (Federico *et al*, 2012).

However, the findings of this study must be interpreted with caution. The use of a retrospective hospital database may have led to variations in the availability of patients' information from medical records, which in turn could have resulted in missing such data as baseline viral load, virus genotypes, risk factors and SVR achievement rates. In order to minimize this inherent weakness, relevant data (as much as possible) were requested from other available records within the hospital. As this study was conducted at a national tertiary care referral center, the distribution of disease stages could po-

tentially be disproportionate towards the more severe stages (referral bias). In addition, while the number of patients in the present study is small, the sparse available evidence suggests only a small proportion of symptomatic HCV patients were in tertiary care, possibly due to the low referral rate and the previous lack of treatment alternatives to IFN (Mohamed R, personal communication). Being the main national referral center for liver disease with the highest numbers of hepatologists and gastroenterologists among Malaysia public hospitals, the patient population in this hospital is likely a good reflection of the affected population treated within tertiary care in Malaysia and the findings in this represent the best available epidemiological data for the country.

In conclusion, this study reveals a relatively high percent liver cirrhosis among HCV-infected patients at initial presentation to a tertiary care center in Malaysia, reflecting delayed referral. The findings also highlights the high number of relatively young patients with cirrhosis at presentation. Data from this study emphasize the importance of timely referral, links to tertiary clinical care centers and the necessity of increasing awareness of HCV infection in the general population. Access to affordable DAA drugs for treatment of hepatitis C within the public healthcare system of Malaysia is essential if the country is to achieve the WHO elimination target for viral hepatitis by 2030.

ACKNOWLEDGEMENTS

This research was partially funded by the University of Malaya through the Frontier Research Grant (FG019-17AFR). We received helpful input from the Director-General of Health of Malaysia, Datuk Dr Noor Hisham Abdullah and his

team at the Ministry of Health Malaysia in developing the research questions. We received kind support and assistance from the former Director of Hospital Selayang, Dr Siti Zaleha Mohd Salleh during data collection. We would like to thank Edward Kah-Hing Wong for his contribution in the preliminary work that informed this study.

REFERENCES

- Alejandro Á, María A. J, Alexandre B, *et al.* Impact of chronic hepatitis C on mortality in cirrhotic patients admitted to intensive-care unit. *BMC Infect Dis* 2016; 16: 1-9.
- Azzeri A, Shabaruddin FH, Mohamed R, *et al.* Cost of treatment for chronic hepatitis C infection at a national tertiary-care referral centre in an Asian middle-income country. *Value Health* 2017; 20: A633.
- Castéra L, Vergniol J, Foucher J, *et al.* Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. *Gastroenterology* 2005; 128: 343-50.
- Curry MP, O'Leary JG, Bzowej N, *et al.* Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. *N Engl J Med* 2015; 373: 2618-28.
- Degos F, Christidis C, Ganne-Carrie N, *et al.* Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. *Gut* 2000; 47: 131-6.
- Department of Statistics Malaysia. Population distribution and basic demographic characteristic report. Putrajaya: Department of Statistic Malaysia, 2010. [Cited 2017 Mar 20]. Available from: <https://www.dosm.gov.my>
- de Oliveira AC, Bortotti AC, Nunes NN, El Bacha I, Parise ER. Association between age at diagnosis and degree of liver injury in hepatitis C. *Brazilian J Infect Dis* 2014; 18: 507-11.
- European Association for the Study of the Liver (EASL). New consensus definition of late presentation for viral hepatitis 2015. Geneva: EASL, 2015.
- Federico CA, Hsu PC, Kraiden M, *et al.* Patient time costs and out-of-pocket costs in hepatitis C. *Liver Int* 2012; 32: 815-25.
- Foster GR, McLauchlan J, Irving W, *et al.* Treatment of decompensated HCV cirrhosis in patients with diverse genotypes: 12 weeks sofosbuvir and NS5A inhibitors with/without ribavirin is effective in HCV genotypes 1 and 3. *Hepatology* 2015; 62: S190-1.
- Galle PR, Forner A, Llovet JM, *et al.* European Association for the Study of the Liver (EASL) Clinical Practice Guidelines: Management of hepatocellular carcinoma. *Hepatology* 2018; 69: 182-236.
- Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. *J Hepatol* 2014; 61: S45-57.
- Gupta V, Kumar A, Sharma P, Bansal N, Singla V, Arora A. Most patients of hepatitis C virus infection in India present late for interferon-based antiviral treatment: an epidemiological study of 777 patients from a north Indian tertiary care center. *J Clin Exp Hepatol* 2015; 5: 134-41.
- Hickman M, Angelis D De, Vickerman P, Hutchinson S. HCV treatment as prevention in people who inject drugs – testing the evidence. *Curr Opin Infect Dis* 2015; 28: 576-82.
- Ho SH, Ng KP, Kaur H, Goh KL. Genotype 3 is the predominant hepatitis C genotype in a multi-ethnic Asian population in Malaysia. *Hepatobil Pancreat Dis Int* 2015; 14: 281-6.
- Hospital Selayang. Official Website of Hospital Selayang 2014. [Cited 2017 Nov 23]. Available from: <http://hselayang.moh.gov.my>
- Khullar V, Firpi RJ. Hepatitis C cirrhosis: new perspectives for diagnosis and treatment. *World J Hepatol* 2015; 7: 1843-55.
- Kim CW, Chang K-M. Hepatitis C virus: virology and life cycle. *Clin Mol Hepatol* 2013; 19: 17-25.

- Lingala S , Ghany MG. Natural history of hepatitis C. *Gastroenterol Clin North Am* 2015; 44: 717-34.
- Maasoumy B , Wedemeyer H. Natural history of acute and chronic hepatitis C. *Best Pract Res Clin Gastroenterol* 2012; 26: 401-12.
- McDonald SA, Innes HA, Aspinall E, *et al.* Prognosis of 1169 hepatitis C chronically infected patients with decompensated cirrhosis in the predirect-acting antiviral era. *J Viral Hepat* 2017; 24: 295-303.
- McDonald SA, Mohamed R, Dahlui M, Naning H , Kamarulzaman A. Bridging the data gaps in the epidemiology of hepatitis C virus infection in Malaysia using multi-parameter evidence synthesis. *BMC Infect Dis* 2014;14: 564.
- Messina JP, Humphreys I, Flaxman A, *et al.* Global distribution and prevalence of hepatitis C virus genotypes. *Hepatology* 2015; 61: 77-87.
- Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. *J Viral Hepat* 2006; 13: 34-41.
- Mohamed NA, Zainol Rashid Z, Wong KK, Abdullah SA , Rahman MM. Hepatitis C genotype and associated risks factors of patients at University Kebangsaan Malaysia Medical Centre. *Pak J Med Sci* 2013; 29: 1142-6.
- Myers RP, Kraiden M, Bilodeau M, *et al.* Burden of disease and cost of chronic hepatitis C infection in Canada. *Can J Gastroenterol Hepatol* 2014; 28: 243-50.
- Nguyen LH, Nguyen MH. Systematic review: Asian patients with chronic hepatitis C infection. *Aliment Pharmacol Ther* 2013; 37: 921-36.
- Novick DM, Enlow RW, Gelb AM, *et al.* Hepatic cirrhosis in young adults: association with adolescent onset of alcohol and parenteral heroin abuse. *Gut* 1985; 26: 8-13.
- Razavi H, Elkhoury AC, Elbasha E, Estes C, Pasini K , Poynard T. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. *Hepatology* 2013; 57: 2164-70.
- Sajja KC, Mohan DP, Rockey DC. Age and ethnicity in cirrhosis. *J Investig Med* 2014; 62: 920-6.
- Scalone L, Fagiuoli S, Ciampichini R, *et al.* The societal burden of chronic liver diseases: results from the COME study. *BMJ Open Gastroenterol* 2015; 2: e000025.
- Silva MJ, Rosa MV, Nogueira PJ, Calinas F. Ten years of hospital admissions for liver cirrhosis in Portugal. *Eur J Gastroenterol Hepatol* 2015; 27: 1320-6.
- Suthar AB , Harries AD. A public health approach to hepatitis C control in low- and middle-income countries. *PLOS Med* 2015; 12: 1-12.
- The American Association for the Study of Liver Diseases and Infectious Diseases Society of America. HCV guidance: recommendations for testing, managing, and treating hepatitis C. Alexandria: American Association for the Study of Liver Diseases, 2017.
- Thein HHH, Yi Q, Dore GGJ , Krahn MDM. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. *Hepatology* 2008; 48: 418-31.
- Toshikuni N, Arisawa T , Tsutsumi M. Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality. *World J Gastroenterol* 2014; 20: 2876-87.
- Vicknasingam B, Narayanan S, Navaratnam V, *et al.* The relative risk of HIV among IDUs not in treatment in Malaysia. *AIDS Care* 2009; 21: 984-91.
- Westbrook RH , Dusheiko G. Natural history of hepatitis C. *J Hepatol* 2014; 61: S58-68.
- World Health Organization (WHO). Global health sector strategy on viral hepatitis 2016-2021. Geneva: WHO, 2016.
- World Health Organization (WHO). 20th WHO Essential Medicines List (EML). Geneva: WHO, 2017.

Yau AHL, Lee T, Ramji A , Ko HH. Rate, delay and predictors of hepatitis C treatment in British Columbia. *Can J Gastroenterol Hepatol* 2015; 29: 315-20.

Zhou M, Li H, Ji Y, Ma Y, Hou F , Yuan P. Hepatitis C virus infection in the general population: a large community-based study in Mianyang, West China. *BioSci Trends* 2015; 9: 97-103.